CANTICANTI home
Back to diseases

Disease hub

Hepatocellular Carcinoma

Open Targets catalogue label: hepatocellular carcinoma

Structured disease–target and disease–drug rows, trial registry mirrors, and linked research signals appear here when they are indexed to this hub key. Sparse pages are expected for newer routes — this is not a claim about biological evidence absence.

Data: Live structured evidence (Supabase)

Source catalogue
—
Imported rows
—
Explorer-eligible
—
Targets w/ drugs
—
Open guided lookup (general disease context)
Also indexed as

hepatocellular carcinoma · EFO_0000182 · hepatocellular adenocarcinoma · liver and intrahepatic bile duct carcinoma · carcinoma of liver · hepatocellular cancer, somatic · carcinoma of liver cells · carcinoma of the liver cells · hepatocellular carcinoma, somatic · liver cell carcinoma · HCC · primary carcinoma of liver cells · primary carcinoma of the liver cells · liver carcinoma · carcinoma, hepatocellular, malignant · hepatoblastoma, somatic · hepatocellular cancer · cancer, hepatocellular · hepatocellular carcinoma, childhood type, somatic · hepatoma · liver cell cancer (hepatocellular carcinoma) · hepatoblastoma · hepatoblastoma caused by somatic mutation · liver cancer · adult primary hepatocellular carcinoma · adult hepatoma · ONCOTREE:HCC · Orphanet:88673 · EFO:0000182 · icd11.foundation:1294035808 · MONDO:0007256 · MedDRA:10007416 · MedDRA:10049010 · NCIT:C3099 · NORD:1907 · MESH:D006528 · ICDO:8170/3 · DOID:684 · NANDO:2200047 · GARD:16773 · ICD10:C22.0 · MedDRA:10024658 · OMIM:114550 · UMLS:C2239176 · MEDGEN:389187 · DOID:686 · COHD:4001171

Limitations & build flags

  • Read-only structured navigator
  • No clinical outcome benefit inferred
  • Trial presence does not imply success
  • Drug identity may require normalization
  • Terminated/withdrawn trials must remain visible
Disease–target coverage
Coverage metrics for this hub when live evidence-graph and catalogue snapshots are available.
Source catalogue associations
—

Open Targets associated-target catalogue count for this disease node — not clinically ranked, validated, or treatment-linked targets.

Imported evidence rows
—

Source evidence rows, not unique targets.

Explorer-eligible targets
—

Targets in the GBM evidence-graph view with default dashboard eligibility.

Targets with drug relationships
—

Distinct active GBM explorer-eligible targets with drug–target mechanism-of-action relationships (disease-scoped; not a global catalogue count).

Disease-linked drugs
—

Unique active drugs linked to this disease in the evidence graph.

Disease-drug evidence edges
—

Active disease–drug evidence edges (methodology detail).

Catalogue and row counts are research inventory signals. They do not mean every association is clinically relevant, validated, druggable, or treatment-linked.